Image

The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit

The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit

Recruiting
19 years and older
All
Phase N/A

Powered by AI

Overview

In the case of cardiogenic shock, the early mortality rate is the highest compared to other types of shock, but it is characterized by a good prognosis and quality of life after recovery, so monitoring the treatment progress is very important to identify the patient's prognosis. However, there are few studies specifically reported on hemodynamic monitoring and prognosis of cardiogenic shock. In addition, as mechanical circulatory support devices are in the spotlight, studies on their effects and safety are starting, but studies on cardiogenic shock are often limited to patients with myocardial infarction.

This study is a prospective and retrospective cohort observational study, we aim to identify factors that can improve prognosis, including various drug treatments, diagnostic techniques, and mechanical circulatory support device by investigating the treatment status and clinical outcomes of patients with cardiogenic shock hospitalized in cardiovascular critical care unit. In addition, the purpose of this study is to investigate the association between the prognosis of patients with cardiogenic shock and the presence of a specialist resident during regular work hours to clarify the role and necessity of a resident specialist in the cardiovascular intensive care unit.

Furthermore, by predicting and treating the clinical course of patients with cardiogenic shock at an early stage, the aim is to reduce the mortality rate and improve the patients' ability to perform daily activities.

Eligibility

Inclusion Criteria:

(prospective)

  1. Patients over 19-year-old
  2. Patients who are hospitalized in the cardiovascular critical care unit for cardiogenic shock or reduced blood pressure due to other causes.

    2-1) In the event that the systolic blood pressure is less than 90mmHg for at least 30 minutes despite fluid treatment, or the use of vasopressor drug is required to maintain systolic blood pressure more than 90mmHg.

    2-2) patients have at least one of the symptoms of peripheral tissue hypoperfusion (cold skin, urineoutput < 30cc/ hour, decreased consciousness, lactate > 2.0mmol/l) or pulmonary edema.

    2-3) Patients supported by Mechanical Circulatory support device

  3. Where the cause of a cardiogenic shock conforms to one or more of the following
    matters
             3-1) In the case of an intervention or surgery has been performed due to coronary
             artery disease, peripheral artery disease, venous thromboembolism, pulmonary artery
             disease, aortic disease, etc.
             3-2) In the case of an intervention or surgery has been performed due to valve
             disease.
             3-3) In the case of the insertion of an instrument in the heart is performed due to
             atrial defect, left atrium, arteriosclerosis, etc.
             3-4) In the case of ablation or surgery, defibrillator implantation, and pacemaker
             implantation.
             3-5) In the case of pericardiocentesis or window formation has been performed due to
             cardiac tamponade.
             3-6) When monitoring is required for hypothermia therapy after spontaneous circulation
             recovery.
             3-7) When monitoring is required after other heart-related procedures or surgery 3-8)
             When monitoring is required after heart transplant
          4. Where a patient or legal representative voluntarily agrees to access medical records
             and data necessary for this study during the entire study period
        (retrospective) Patients over 19-year-old who treated in the cardiovascular critical care
        unit from January 1, 2018 to the IRB approval date for decreased blood pressure or needed
        intensive monitoring of vital signs.
        Exclusion Criteria:
          1. A patient with irreparable brain damage.
          2. If there are no witnesses outside the hospital during cardiac arrest.
          3. DNR(Do Not Resuscitate) patients

Study details
    Cardiogenic Shock

NCT05415332

Yonsei University

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.